286 related articles for article (PubMed ID: 35337836)
1. The Functional Roles of Immune Cells in Primary Liver Cancer.
Pham L; Kyritsi K; Zhou T; Ceci L; Baiocchi L; Kennedy L; Chakraborty S; Glaser S; Francis H; Alpini G; Sato K
Am J Pathol; 2022 Jun; 192(6):826-836. PubMed ID: 35337836
[TBL] [Abstract][Full Text] [Related]
2. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
Wang C; Chen C; Hu W; Tao L; Chen J
Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
[TBL] [Abstract][Full Text] [Related]
3. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.
Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T
Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764
[TBL] [Abstract][Full Text] [Related]
4. Prognostic values of tissue-resident CD8
Chen L; Huang H; Huang Z; Chen J; Liu Y; Wu Y; Li A; Ge J; Fang Z; Xu B; Zheng X; Wu C
World J Surg Oncol; 2023 Apr; 21(1):124. PubMed ID: 37024870
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of cancer stemness maintenance in human liver cancer.
Liang N; Yang T; Huang Q; Yu P; Liu C; Chen L; Wang Q; Wang G; He X
Cell Death Dis; 2022 Apr; 13(4):394. PubMed ID: 35449193
[TBL] [Abstract][Full Text] [Related]
6. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.
Liu D; Heij LR; Czigany Z; Dahl E; Lang SA; Ulmer TF; Luedde T; Neumann UP; Bednarsch J
J Exp Clin Cancer Res; 2022 Apr; 41(1):127. PubMed ID: 35392957
[TBL] [Abstract][Full Text] [Related]
7. Propensity-Matched Analysis of Patients with Mixed Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma Undergoing Liver Transplantation.
Lunsford KE; Court C; Seok Lee Y; Lu DS; Naini BV; Harlander-Locke MP; Busuttil RW; Agopian VG
Liver Transpl; 2018 Oct; 24(10):1384-1397. PubMed ID: 29573187
[TBL] [Abstract][Full Text] [Related]
8. Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.
Cao H; Huang T; Dai M; Kong X; Liu H; Zheng Z; Sun G; Sun G; Rong D; Jin Z; Tang W; Xia Y
Int J Biol Sci; 2022; 18(14):5369-5390. PubMed ID: 36147461
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the distinct immune microenvironments between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Jiang S; Lu H; Pan Y; Yang A; Aikemu A; Li H; Hao R; Huang Q; Qi X; Tao Z; Wu Y; Quan C; Zhou G; Lu Y
Cancer Lett; 2024 Apr; 588():216799. PubMed ID: 38479553
[TBL] [Abstract][Full Text] [Related]
10. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
Zhang Q; Lou Y; Bai XL; Liang TB
World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
[TBL] [Abstract][Full Text] [Related]
11. Proteome Landscapes of Human Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
Yi X; Zhu J; Liu W; Peng L; Lu C; Sun P; Huang L; Nie X; Huang S; Guo T; Zhu Y
Mol Cell Proteomics; 2023 Aug; 22(8):100604. PubMed ID: 37353004
[TBL] [Abstract][Full Text] [Related]
12. Tumor Microenvironment: Necroptosis Switches the Subtype of Liver Cancer While Necrosis Promotes Tumor Recurrence and Progression.
Özdemir BH
Exp Clin Transplant; 2023 Apr; 21(4):291-298. PubMed ID: 35297332
[TBL] [Abstract][Full Text] [Related]
13. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).
Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H
Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583
[TBL] [Abstract][Full Text] [Related]
14. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies.
Argemi J; Ponz-Sarvise M; Sangro B
Adv Cancer Res; 2022; 156():367-413. PubMed ID: 35961706
[TBL] [Abstract][Full Text] [Related]
16. Plasma proteome atlas for differentiating tumor stage and post-surgical prognosis of hepatocellular carcinoma and cholangiocarcinoma.
Chang TT; Ho CH
PLoS One; 2020; 15(8):e0238251. PubMed ID: 32845921
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker.
Utispan K; Thuwajit P; Abiko Y; Charngkaew K; Paupairoj A; Chau-in S; Thuwajit C
Mol Cancer; 2010 Jan; 9():13. PubMed ID: 20096135
[TBL] [Abstract][Full Text] [Related]
18. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers.
Zhou G; Boor PPC; Bruno MJ; Sprengers D; Kwekkeboom J
Br J Cancer; 2022 Jan; 126(1):10-23. PubMed ID: 34400801
[TBL] [Abstract][Full Text] [Related]
19. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma.
Lee JH; Chung GE; Yu SJ; Hwang SY; Kim JS; Kim HY; Yoon JH; Lee HS; Yi NJ; Suh KS; Lee KU; Jang JJ; Kim YJ
J Clin Gastroenterol; 2011 Jan; 45(1):69-75. PubMed ID: 20142755
[TBL] [Abstract][Full Text] [Related]
20. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Lee WS; Lee KW; Heo JS; Kim SJ; Choi SH; Kim YI; Joh JW
Surg Today; 2006; 36(10):892-7. PubMed ID: 16998683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]